ARTICLE | Clinical News

Gamunex immune globulin intravenous: Additional Phase III data

September 29, 2008 7:00 AM UTC

Data from a sub-group analysis of 32 responders in a Phase III trial, showed that 41% of responders improved after the first Gamunex treatment course (day 16) and 94% improved after the second Gamunex...